Kidron Nadav's most recent trade in Oramed Pharmaceuticals, Inc was a trade of 186,000 Common Stock done . Disclosure was reported to the exchange on Feb. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 186,000 | 2,586,598 (14%) | 1% | 0 | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 141,000 | 2,400,598 (13%) | 0% | 0 | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 100,000 | 2,686,598 (15%) | 0% | 0 | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 433,500 | 2,259,598 (12%) | 2% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 45,000 | 1,826,098 (10%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 329,000 | 1,781,098 (9%) | 1% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 120,000 | 1,452,098 (8%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 279,000 | 1,332,098 (7%) | 1% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 16 Mar 2023 | 26,000 | 126,000 (0%) | 0% | 2.0 | 53,014 | Common Stock |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.01 per share. | 14 Mar 2023 | 100,000 | 100,000 (0%) | 0% | 2.0 | 201,000 | Common Stock |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 126,000 | 1,090,729 (6%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 34,000 | 964,729 (5%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 28 Jul 2022 | 12,631 | 1,078,098 (6%) | 0% | 8.4 | 105,595 | Common Stock |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 150,000 | 916,481 (5%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 107,000 | 107,000 | - | - | Stock Option (right to buy | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 63,000 | 930,729 (5%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 03 Jan 2022 | 48,752 | 867,729 (4%) | 0% | 13.9 | 677,165 | Common Stock |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.98 per share. | 28 Dec 2021 | 31,728 | 786,481 (4%) | 0% | 13.0 | 411,829 | Common Stock |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2021 | 20,000 | 766,481 (4%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2021 | 100,000 | 748,573 (4%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.11 per share. | 09 Aug 2021 | 220,000 | 648,573 (3%) | 1% | 20.1 | 4,423,144 | Common Stock |
| Oramed Pharmaceuticals, Inc | Kidron Nadav | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 150,000 | 150,000 | - | - | Stock Option (right to buy) |